Compare Abbott Laboratories (ABT) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Xcel Energy Inc — how do they compare? Abbott Laboratories trades at $111.1 (market cap $187.95B), while Xcel Energy Inc trades at $78.11 (market cap $48.51B). The key difference: Abbott Laboratories is far larger — about 3.9× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| ABT | XEL | |
|---|---|---|
Market Cap | $187.95B | $48.51B |
Sector | Health | Utilities |
52-Week High | $136.62 | $83.91 |
52-Week Low | $82.57 | $71.75 |
Enterprise Value | $214.96B | $86.82B |
Dividend Yield | 2.32% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
XEL trades at $78.09, up 1.59% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations in Q2 2026 with EPS of $0.93, driven by infrastructure investments. The company maintains solid fundamentals, including a 15.28% net income margin and a $0.59 quarterly dividend, while analyst consensus is bullish with a $93.80 price target.
Outlook is positive due to strong earnings growth and a $60 billion capital plan supporting future expansion, but risks include regulatory pushback and high debt levels. The stock offers stability with a 2.87% dividend yield, though technical resistance near $79 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
